Drugs / DTaP-IPV//PRP∼T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00453570 | Mar 2007 → Dec 2008 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-IPV//PRP∼T | “This study assessed the antibody persistence, and the immunogenicity and safety of a booster dose of a DTaP-IPV//PRP∼T (Pentaxim®, Sanofi Pasteur's AcXim family) combined vaccine” PMID 22001281 ↗ Oct 2011 |
| Known as | Pentaxim() | “This study assessed the antibody persistence, and the immunogenicity and safety of a booster dose of a DTaP-IPV//PRP∼T (Pentaxim®, Sanofi Pasteur's AcXim family) combined vaccine” PMID 22001281 ↗ Oct 2011 |
| Modality | Vaccine | “a DTaP-IPV//PRP∼T (Pentaxim®, Sanofi Pasteur's AcXim family) combined vaccine” PMID 22001281 ↗ Oct 2011 |